Author's response to reviews

Title: Safety and efficacy of vemurafenib in end stage renal failure.

Authors:

Mahesh Iddawela (mahesh.iddawela@unimelb.edu.au)
Sarah Cook (sarahcook@gmail.com)
Leah George (leahcge@hotmail.com)
Amit Lakkaraju (amitlakkaraju@gmail.com)
Nihal Nanayakkara (nihal.nana@gvhealth.org.au)
Roland Hunt (Roland.Hunt@gvhealth.org.au)
William R Adam (wadam@unimelb.edu.au)

Version: 2 Date: 8 November 2013

Author's response to reviews: see over
Dear Dr. Riker,

Ref MS: 1104803223103505: Safety and efficacy of vemurafenib in end stage renal failure.

Thank you for the peer review and comments on the case report and these were very helpful in improving the manuscript. I have addressed the comments below and had been addressed in the manuscript as well.

Reviver 1:
1-Please provide rationale for attributing drug induced QTc when there was a history of such fluctuation 2 years prior?
As prolong QTc is a toxicity associated with vemurafenib, it was initially assumed to be due to the drug and investigated further and the previous history was only discovered on retrospective review. Further analysis and investigations showed that it was unlikely, especially as the Naranjo scale was low.

2-Use validated probability score such as Naranjo et al. for attribution.
Thank you the comment and the paper has been edited using this information. The score was low hence suggesting there is a low chance of drug involved in causing this reaction and this has been amended.

3-Show 12 lead ECG to show morphology and ascertain if the patient had congenital LQTS.
A twelve lead ECG has been included Figure 1.

Reviver 2:

No Specific changes except editing, which has been done.

Editorial comments- Include consent statement is updated. This has been included and patient consent form uploaded as well.

I have addressed all the queries raised and would be happy to provide more information if needed.

Yours faithfully

Mahesh Iddawela